Pharma Pulse: Transparency Mandates and the Novartis Patent Storm
Feb 05, 10:30 AM
Share
Subscribe
In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, while Novartis braces for the largest patent expiration cycle in its history.
